Boji Pharmaceutical (300404.SZ): “FCZR” obtains drug clinical trial approval notice

Zhitong Finance App News, Boji Pharmaceutical (300404.SZ) issued an announcement. Recently, the “FCZR” declared by the company obtained the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration.

FCZR is a 2.2/2.4 improved new drug that optimizes dosage forms, prescription processes, administration routes, indications, etc. on the basis of known active ingredients, and has obvious clinical advantages. The proposed indication is otomycosis. Otomycosis is a common type of infectious disease in otolaryngology clinics. It is common in hot and humid seasons and regions, and is often recurrent and difficult to cure. The FCZR dosage form has the advantages of fluidity and easy administration. Ear drops can directly contact lesions in various hidden corners of the ear canal, and exert the local effects of local administration. Currently, no such drug has been approved for marketing at home or abroad, and there is no relevant sales data.